Abstract
According to international guidelines, treatment of cervical cancer (CC) consists of surgery in early stages and of chemoradiation in locally advanced disease. Metastatic disease is usually treated with palliative chemotherapeutic regimens, but cytostatic drugs present significant side effects and show limited activity. Thus, the discovery of new anticancer agents, interfering with molecular targets expressed by the tumor’s microenvironment or by the tumor cell itself, represents a possible chance for the struggle against this tumor. The aim of this review is to report all targets that have been investigated in preclinical and clinical studies. We discuss these potential targets according to “targeted therapies” NCI classification. The most investigated molecular targets have been epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), both involved in CC etiopathogenesis. Studies with anti-angiogenetic agents showed encouraging clinical efficacy and acceptable toxicity. Other interesting results have been obtained by immunotherapeutic strategies. Since biological characteristics of CC, especially in recurrent disease, are still partially unknown, future studies are necessary to understand mechanisms involved in CC carcinogenesis, in order to give to patients the most tailored and efficient treatments.
Keywords: Cervical cancer, molecular pathways, preclinical studies, targeted therapies.
Current Drug Targets
Title:Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results
Volume: 15 Issue: 12
Author(s): Federica Tomao, Chiara Di Tucci, Ludovica Imperiale, Serena Maria Boccia, Claudia Marchetti, Innocenza Palaia, Ludovico Muzii and Pierluigi Benedetti Panici
Affiliation:
Keywords: Cervical cancer, molecular pathways, preclinical studies, targeted therapies.
Abstract: According to international guidelines, treatment of cervical cancer (CC) consists of surgery in early stages and of chemoradiation in locally advanced disease. Metastatic disease is usually treated with palliative chemotherapeutic regimens, but cytostatic drugs present significant side effects and show limited activity. Thus, the discovery of new anticancer agents, interfering with molecular targets expressed by the tumor’s microenvironment or by the tumor cell itself, represents a possible chance for the struggle against this tumor. The aim of this review is to report all targets that have been investigated in preclinical and clinical studies. We discuss these potential targets according to “targeted therapies” NCI classification. The most investigated molecular targets have been epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), both involved in CC etiopathogenesis. Studies with anti-angiogenetic agents showed encouraging clinical efficacy and acceptable toxicity. Other interesting results have been obtained by immunotherapeutic strategies. Since biological characteristics of CC, especially in recurrent disease, are still partially unknown, future studies are necessary to understand mechanisms involved in CC carcinogenesis, in order to give to patients the most tailored and efficient treatments.
Export Options
About this article
Cite this article as:
Tomao Federica, Tucci Di Chiara, Imperiale Ludovica, Boccia Maria Serena, Marchetti Claudia, Palaia Innocenza, Muzii Ludovico and Panici Benedetti Pierluigi, Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results, Current Drug Targets 2014; 15 (12) . https://dx.doi.org/10.2174/1389450115666141010145547
DOI https://dx.doi.org/10.2174/1389450115666141010145547 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy
Current Cancer Drug Targets Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Anti-Proliferative, Anti-Inflammatory, Anti-Ulcerogenic and Wound Healing Properties of Chitosan
Current Bioactive Compounds <sup>18</sup>F-DOPA and <sup>18</sup>F-FDG PET/CT, Scintigraphic Localization and Radioguided Surgery of Recurrent Medullary Thyroid Cancer: Two Case Reports
Current Radiopharmaceuticals FDG-PET in Tuberculosis
Current Molecular Imaging (Discontinued) AAV as An Immunogen
Current Gene Therapy Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer
Current Molecular Medicine Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA Epothilones: A Novel Class of Non-taxane Microtubule-stabilizing Agents
Current Pharmaceutical Design Targeting Autophagic Pathways by Plant Natural Compounds in Cancer Treatment
Current Drug Targets Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy
Current Cancer Drug Targets Molecular Docking and Dynamic Simulation Studies of Terpenoids of I. wightii (Bentham) H. Hara against Acetylcholinesterase and Histone Deacetylase3 Receptors
Current Computer-Aided Drug Design Inflammation and Pancreatic Cancer: Recent Development with Focusing on Potential New Drug Targets
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Advancement of Targeted Ultrasound Contrast Agents and their Applications in Molecular Imaging and Targeted Therapy
Current Pharmaceutical Design Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Review of the Phytochemistry and Biological Activity of Cissus incisa Leaves
Current Topics in Medicinal Chemistry Abscopal Effect of Radiation Therapy and Signal Transduction
Current Signal Transduction Therapy